An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis (NEXT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02454205|
Recruitment Status : Completed
First Posted : May 27, 2015
Last Update Posted : September 29, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Tuberculosis Multidrug Resistant Tuberculosis Extensively-drug Resistant Tuberculosis||Drug: Linezolid Drug: Bedaquiline Drug: Levofloxacin Drug: Pyrazinamide Drug: Isoniazid Drug: Ethionamide Drug: Terizidone Drug: Moxifloxacin Drug: Kanamycin||Phase 2 Phase 3|
TB is completely out of control in South Africa and is now officially the most common cause of death in this country. Alarmingly, the gravity if this pandemic has now been compounded by the emergence of multidrug-resistant TB (MDR-TB), which constitutes resistance to the two most potent anti-tuberculous drugs, namely rifampicin and isoniazid . XDR-TB refers to resistance to rifampicin, isoniazid, any fluoroquinolone, and any second line injectable drug (amikacin, kanamycin, or capreomycin). MDR-TB is a burgeoning epidemic in South Africa, with rates trebling over the last decade. It is of considerable concern because mortality is high (up to 50% in South Africa) and it often affects economically active young adults. It is also a major threat to health care workers in South Africa. We recently showed a rate in SA health care workers 6 fold higher than the general population further exacerbating the shortage of this critical workforce in the country. The increasing cost to manage this disease is unsustainable.
Although drug-resistant TB comprises less than 2% of the total caseload in the country (approximately ½ million patients with TB treated per year), it consumes almost 40% of the total national TB programme budget, and more than 60% of the total TB drug budget. This is not sustainable and drug-resistant TB therefore has the capacity to destabilise functional TB control programmes in many countries in Africa.
The treatment of MDR-TB is arduous, with a six to eight month intensive phase of daily painful injections of Kanamycin combined with oral pyrazinamide, a fluoroquinolone (moxifloxacin or levofloxacin), prothionamide and either cycloserine or para-aminosalicylic acid (if cycloserine cannot be used). Treatment continues for 18 months after consecutive negative sputum cultures, and lasts at least 20 months. There are substantial drug-associated toxicities and adverse events that frequently lead to interruption or cessation of treatment.
This study proposes to test the efficacy of a new drug regimen for the treatment of MDR-TB which is of short term duration and which does not contain an injectable drug, thus making treatment easier to administer and thereby potentially increasing compliance. All the drugs will be available to the NTP if the study is shown to be successful. This regimen will comprise linezolid, bedaquiline, levofloxacin, PZA and either ethionamide or high dose INH or teridazone. A gene-directed diagnostic approach (mutational analysis) will be used in the interventional arm to individualise therapy and to inform on the use of high dose INH versus ethionamide. If both mutations are present then to administer teridazone.
Furthermore, in the proposed study the key aim is to test a regimen (rather than an individual drug) and will look at how the outcomes (24 month), including treatment completion/cure (i.e. treatment success which is the primary outcome) and mortality, are impacted. It is expected that introduction of a shortened effective regimen will reduce drop out and drastically reduce mortality and on-going transmission. Moreover, the rates of XDR-TB and TDR-TB may also decline.
The study will be conducted at 5 trial sites in South Africa that are designated MDR-TB treatment facilities and it many cases patients will be recruited from the satellite clinics of these centres reflecting the decentralized MDR-TB program. All the sites have the necessary expertise and facilities to carry out the proposed study. The study is a fully conceived and funded within South Africa.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||154 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial|
|Actual Study Start Date :||November 12, 2015|
|Actual Primary Completion Date :||December 31, 2020|
|Actual Study Completion Date :||August 30, 2021|
Active Comparator: Conventional treatment 21-24 months
Participants will receive a 6-8 month intensive phase of: Kanamycin IM 500-750mg (40-50kg) or 1000mg (51-90kg) daily, Moxifloxacin 400mg od, Pyrazinamide 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily,Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.
The continuation phase will start after 2 consecutive negative sputum cultures and continue for 18 months with Moxifloxacin, PZA, Ethionamide and Terizidone.
In 2016 the WHO revised the treatment guidelines for MDR-TB. The South African National Tuberculosis Program adopted these recommendations and it was integrated into the study in September 2016: SA NTP recommended shorter regimen(9-12 months):Intensive phase (4-6 months): kanamycin, levofloxacin, clofazimine, pyrazinamide, high-dose isoniazid/ethionamide, ethambutol. Continuation phase (5 months): levofloxacin, clofazimine, pyrazinamide, ethambutol.
1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
Other Name: PZA
15mg/kg (max 900mg)
750mg (40-70kg) 750-1000mg (71-90kg)
400mg po daily.
500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
Experimental: Interventional treatment 6-9 months
Participants will receive six to nine months of oral:
Linezolid 600mg daily (reduce to 300mg if toxicity occurs), Bedaquiline 400mg for 2 weeks, followed by 200mg three times per week, Levofloxacin 750mg (<50kg) or 1000mg (>50kg) daily, PZA 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 15mg/kg (max 900mg) daily, or high-dose Isoniazid 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily, or Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.
A gene-directed diagnostic approach will be used in the interventional arm to individualise therapy and to inform on the use of high dose INH versus ethionamide. Treatment will stop after 3 consecutive negative sputum cultures.
600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.
400mg po daily for 2 weeks, followed by 200mg three times per week .
750mg (<50kg) 1000mg (>50kg)
1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
Other Name: PZA
high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)
Other Name: INH
15mg/kg (max 900mg)
750mg (40-70kg) 750-1000mg (71-90kg)
- Treatment success [ Time Frame: 24 months after initiation of treatment in either arm. ]In the conventional arm treatment success is defined as the sum of cured or treatment completed cases. In the intervention arm treatment success is defined as the sum of cured and treatment completed cases, without subsequent relapse, re-infection or death during the 15-18 month follow up period.
- Favourable outcome rate [ Time Frame: At 6-9 months for the intervention arm and 21-24 months for the conventional arm. ]
- Time specific rate of treatment failure. [ Time Frame: 6-36 months ]
- Time specific culture conversion proportions and rates. [ Time Frame: 6-36 months ]
- Time specific relapse rate. [ Time Frame: 6-36 months. ]
- Rate of re-infection. [ Time Frame: 6-36 months. ]
- All cause mortality [ Time Frame: 0-36 months. ]
- Composite measure of QT interval on ECG, grade 3 and 4 adverse events, stopping drugs Safety and tolerability end-points. [ Time Frame: 0-36 months. ]
- Default rate [ Time Frame: 2-24 months ]Rate at which participants interrupt treatment for two or more consecutive months for any reason without medical approval.
- Rate of loss of follow-up. [ Time Frame: 0-36 months. ]Rate at which a participant becomes untraceable at any point in the study, and remains untraceable at completion of study despite every effort being made by researchers to locate the participant.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Newly diagnosed culture and/or GeneXpert positive pulmonary TB.
- Rifampicin resistance detected using at least two susceptibility testing assays (GeneXpert, HainMTBDRplus or phenotypic) using a sputum sample during screening.
- Provide written informed consent prior to all trial-related procedures including HIV testing.
- Male or female aged 18 years and older.
- Body weight between 40 and 90 kg, inclusive.
- Women of non-childbearing potential or participants of either sex who are using or willing to use effective methods of birth control
- A participant who in the opinion of the investigator is unlikely to cope with regular visits to the trial site either because of travel constraints, or because of drug or alcohol abuse, or other reason.
- Known at screening to have XDR-TB or pre-XDR-TB (i.e. fluoroquinolone or second-line injectable drug (SLID) resistance i.e. to capreomycin, amikacin and kanamycin).
- Previous history of treatment for MDR-TB or XDR-TB or previous treatment with bedaquiline.
- Currently on MDR-TB treatment for more than 2 weeks.
- Any participant with a Karnofsky score < 50.
- Known allergy to any of the trial drugs or related substances.
- Having participated in other clinical studies within 8 weeks prior to trial start where investigational agents were used that may potentially impact current trial outcome.
- Presence (or evidence) of symptomatic neuropathy grade 3 or higher.
- Epilepsy where drugs prolonging QT interval are used.
- Participant who is pregnant, breast-feeding (and not willing to stop), or planning to conceive a child within 6 months of cessation of treatment.
- Incompatibility between microbiological and clinical/ radiological findings (i.e. where the clinical and/or radiological findings are discordant with microbiological testing suggesting laboratory contamination).
- Participants with ECG abnormalities, in particular QT prolongation.
Any pre-existing laboratory abnormality which in the opinion of the investigator will place the participant at risk. Patients with any of the following baseline laboratory abnormalities will be excluded from the study:
- Creatinine grade 2 or worse (>1.4 times ULN)
- Hemoglobin level grade 4 (HB <6.5g/dL)
- Platelets grade 3 or worse (<49999 x 109/L)
- ALT grade 3 or worse (>5 times ULN)
- Total bilirubin grade 3 or worse (>2.5 times ULN)
- Specific prior or concurrent medication/treatments (see Restrictions section below, Table 3).
- Rifampicin monoresistant TB.
- Fluoroquinolone and/or SLID resistance. Although in South Africa, the standard of care does not single out MDR-TB with fluoroquinolone or aminoglycoside resistance at initiation of MDR-TB treatment, in this study the Hain MTBDRsl LPA will be used on the sputum sample to exclude any pre-XDR and XDR cases from participation in the study (results from the LPA and phenotypic DST testing on the isolate will be available 3-6 weeks later).
All inclusion and no exclusion criteria must be met prior to enrolment and randomisation. Whenever the investigator has reason to suspect that there might be a health problem (other than TB) participation should only be considered after discussing the case with the medical monitor. Note: Participants who are currently on, or have previously been on drug-sensitive TB treatment are not excluded from participation.
Post-randomisation exclusion criteria:
• Fluoroquinolone and/or SLID resistance detected on DST using the isolate. Note: A woman who falls pregnant during the treatment phase of the trial will not be excluded but will be counselled regarding potential termination of pregnancy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02454205
|Brooklyn Chest Hospital|
|Cape Town, Western Cape, South Africa, 7441|
|Principal Investigator:||Keertan Dheda, MBChB||UCT Lung Institute|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Keertan Dheda, Principle Investigator, University of Cape Town|
|Other Study ID Numbers:||
|First Posted:||May 27, 2015 Key Record Dates|
|Last Update Posted:||September 29, 2021|
|Last Verified:||September 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
Extensively Drug-Resistant Tuberculosis
Gram-Positive Bacterial Infections
Bacterial Infections and Mycoses
Topoisomerase II Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents, Urinary
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Fatty Acid Synthesis Inhibitors